Original news and analysis on international IP policy
Non-profit patent researchers studying the most prominent prescription insulin drug to treat diabetes in the United States found it is “overpatented” and “overpriced,” enabling unwarranted price-hikes resulting in rising costs for patients and taxpayers.
French advocacy group La Quadrature du Net has declared recent French government plans to regulate internet hate speech insufficient, and is calling for more in-depth reforms. These could include the promotion of alternative social media platforms and a decentralised approach to regulation, according to an organisation press release.
Public Knowledge, a Washington, DC advocacy group, today released a paper calling for the formation of a new federal government authority to develop expertise and capacity on artificial intelligence (AI), to be able to effectively regulate and govern these technologies in the future.
A new report reviews how patent linkage mechanisms have been implemented in South Korea, Australia, Canada, and the United States, and identifies precedents for how low and middle-income countries (LMICs) can retain and exploit “constructive ambiguities” in trade treaty text to mitigate the impacts of patent linkage mechanisms and promote the timely availability of generic medicines.
BARCELONA, Spain -- The Internet Corporation for Assigned Names and Numbers (ICANN) is struggling over Europe's privacy legislation. Is there a data “war” in the making? It is exactly 20 years since the founding of ICANN and two years after being finally fully privatized, and the self-regulatory internet domain name body has been named a “practical peace project underway” by its President and CEO Göran Marby. But it is now struggling with an old issue: privacy and access to personal information in the Whois database.
Negotiations on possible exceptions to copyright for specific actors such as libraries, archives, universities and research institutions at the World Intellectual Property Organization have been stalling for years. Last week, a group of civil society organisations published a proposed draft treaty text for copyright exceptions for educational and research activities. Now they are seeking support from WIPO members to shoulder the text.
WASHINGTON, DC -- More than 400 activists, academics and practitioners from over 50 countries gathered at this year’s Global Congress on Intellectual Property and the Public Interest, according to organisers. At the Congress, participants shared success stories, developed strategies, and engaged in critical dialogue to re-think and re-invent intellectual property systems that serve the public interest.
The European Union has ratified the global treaty establishing copyright exceptions for visually impaired people today at the World Intellectual Property Organization, bringing the total rapidly growing membership to 70 and increasing the number of available books. Accessing the treaty is just part of the work, according to a global librarian association, as implementation of the treaty is key to accessibility for visually impaired people. The group published its 2018 monitoring report of the treaty implementation.
The United Nations Human Rights Council last week passed a resolution on the rights of peasants, to be confirmed by the UN General Assembly in November. The resolution includes an article on the right to seeds, and in particular the right to save, use, exchange and sell farm-saved seeds, which has been a longstanding demand of peasants' organisations. The resolution also asks that seed policies and intellectual property laws take into account the rights, needs and realities of peasants.
Luiz Otávio Pimentel is president of the National Institute of Industrial Property (INPI) of Brazil. In Geneva this week for the annual World Intellectual Property Organization General Assemblies he took time to sit down with Intellectual Property Watch’s William New. INPI is part of the Ministry of Industry, Foreign Trade and Services. On a breaking issue, Pimentel talked about the case in Brazil involving sofosbuvir, marketed as Sovaldi, Gilead’s effective medicine against hepatitis C that has been known for its exorbitant prices.